MXCT vs. HRTX, MGTX, ANAB, MGNX, NRC, OABI, ABSI, HBIO, LUNA, and NOTV
Should you be buying MaxCyte stock or one of its competitors? The main competitors of MaxCyte include Heron Therapeutics (HRTX), MeiraGTx (MGTX), AnaptysBio (ANAB), MacroGenics (MGNX), National Research (NRC), OmniAb (OABI), Absci (ABSI), Harvard Bioscience (HBIO), Luna Innovations (LUNA), and Inotiv (NOTV).
MaxCyte (NASDAQ:MXCT) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, community ranking, profitability and risk.
MaxCyte has higher earnings, but lower revenue than Heron Therapeutics. MaxCyte is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.
Heron Therapeutics has a net margin of -61.28% compared to MaxCyte's net margin of -83.00%. Heron Therapeutics' return on equity of 0.00% beat MaxCyte's return on equity.
MaxCyte has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500.
MaxCyte currently has a consensus price target of $8.67, suggesting a potential upside of 93.45%. Heron Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 48.65%. Given MaxCyte's higher possible upside, equities analysts clearly believe MaxCyte is more favorable than Heron Therapeutics.
In the previous week, Heron Therapeutics had 7 more articles in the media than MaxCyte. MarketBeat recorded 9 mentions for Heron Therapeutics and 2 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.93 beat Heron Therapeutics' score of 0.66 indicating that MaxCyte is being referred to more favorably in the media.
Heron Therapeutics received 646 more outperform votes than MaxCyte when rated by MarketBeat users. However, 84.62% of users gave MaxCyte an outperform vote while only 69.01% of users gave Heron Therapeutics an outperform vote.
68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 3.0% of MaxCyte shares are owned by company insiders. Comparatively, 6.4% of Heron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Heron Therapeutics beats MaxCyte on 9 of the 17 factors compared between the two stocks.
Get MaxCyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
